Use este identificador para citar ou linkar para este item: https://repositorio.ufpa.br/jspui/handle/2011/7002
Registro completo de metadados
Campo DCValorIdioma
dc.creatorJUSTINO, Maria Cleonice Aguiar-
dc.creatorARAÚJO, Eliete da Cunha-
dc.creatorVAN DOORN, Leen-Jan-
dc.creatorOLIVEIRA, Consuelo Silva de-
dc.creatorGABBAY, Yvone Benchimol-
dc.creatorMASCARENHAS, Joana D'Arc Pereira-
dc.creatorMIRANDA, Yllen Stefania Affonso-
dc.creatorGUERRA, Sylvia de Fátima dos Santos-
dc.creatorSILVA, Veronilce Borges da-
dc.creatorLINHARES, Alexandre da Costa-
dc.date.accessioned2015-11-17T13:44:38Z-
dc.date.available2015-11-17T13:44:38Z-
dc.date.issued2012-11-
dc.identifier.citationJUSTINO, Maria Cleonice Aguiar et al. Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 107, n. 7, p. 846-853, nov. 2012. Disponível em: <http://www.scielo.br/pdf/mioc/v107n7/02.pdf>. Acesso em: 16 nov. 2015. <http://dx.doi.org/10.1590/S0074-02762012000700002>.pt_BR
dc.identifier.issn0074-0276-
dc.identifier.urihttp://repositorio.ufpa.br/jspui/handle/2011/7002-
dc.description.abstractIn a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3% [95% confidence interval (CI) 37.5-89.1%] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8% (95% CI 36.4-96.6%) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.pt_BR
dc.description.provenanceSubmitted by Cleide Dantas (cleidedantas@ufpa.br) on 2015-11-16T13:03:00Z No. of bitstreams: 2 license_rdf: 22190 bytes, checksum: 19e8a2b57ef43c09f4d7071d2153c97d (MD5) Artigo_OralLiveAttenuated.pdf: 445376 bytes, checksum: fe8778b5f39cb83d83ad6fa7a5f84513 (MD5)en
dc.description.provenanceApproved for entry into archive by Ana Rosa Silva (arosa@ufpa.br) on 2015-11-17T13:44:38Z (GMT) No. of bitstreams: 2 license_rdf: 22190 bytes, checksum: 19e8a2b57ef43c09f4d7071d2153c97d (MD5) Artigo_OralLiveAttenuated.pdf: 445376 bytes, checksum: fe8778b5f39cb83d83ad6fa7a5f84513 (MD5)en
dc.description.provenanceMade available in DSpace on 2015-11-17T13:44:38Z (GMT). No. of bitstreams: 2 license_rdf: 22190 bytes, checksum: 19e8a2b57ef43c09f4d7071d2153c97d (MD5) Artigo_OralLiveAttenuated.pdf: 445376 bytes, checksum: fe8778b5f39cb83d83ad6fa7a5f84513 (MD5) Previous issue date: 2012-11en
dc.language.isoengpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectGastroenteritept_BR
dc.subjectRotavíruspt_BR
dc.subjectEficácia da vacinapt_BR
dc.subjectBelém - PApt_BR
dc.subjectPará - Estadopt_BR
dc.subjectAmazônia brasileirapt_BR
dc.titleOral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian childrenpt_BR
dc.typeArtigo de Periódicopt_BR
Aparece nas coleções:Artigos Científicos - FAMED/ICS

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Artigo_OralLiveAttenuated.pdf434,94 kBAdobe PDFVisualizar/Abrir


Este item está licenciado sob uma Licença Creative Commons Creative Commons